Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Mesoblast Ltd

Healthcare AU MSB

2.27AUD
0.10(4.61%)

Last update at 2026-06-24T01:25:00Z

Day Range

2.192.27
LowHigh

52 Week Range

1.533.31
LowHigh

Fundamentals

  • Previous Close 2.17
  • Market Cap2663.22M
  • Volume1243516
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-64.33900M
  • Revenue TTM65.38M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM -23.23400M
  • Diluted EPS TTM-0.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -101.81200M -88.14700M -82.10100M -91.58600M -99.63000M
Minority interest - - - - -
Net income -102.14200M -87.95600M -81.88900M -91.34700M -98.81100M
Selling general administrative 23.21M 23.63M 25.37M 27.21M 30.87M
Selling and marketing expenses 16.10M 15.72M 27.73M 30.76M 32.72M
Gross profit 12.07M -35.16800M -47.42100M -53.36100M -78.27500M
Reconciled depreciation 6.40M 4.67M 4.11M 4.38M 4.26M
Ebit -80.05900M -57.97200M -69.13600M -80.95300M -111.86700M
Ebitda -73.65900M -56.07700M -65.02900M -76.57300M -107.60300M
Depreciation and amortization 6.40M 1.90M 4.11M 4.38M 4.26M
Non operating income net other - - - - -
Operating income -62.44300M -84.14700M -69.28900M -80.57400M -109.09600M
Other operating expenses 79.64M 90.05M 76.79M 90.78M 115.06M
Interest expense 21.75M 20.66M 19.44M 16.91M 10.71M
Tax provision 0.33M -0.19100M -0.21200M -0.23900M -0.81900M
Interest income 3.55M 1.82M 18.78M 0.00300M 14.47M
Net interest income -18.99800M -18.83400M -19.29100M -17.28500M -10.71400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.33M -0.19100M -0.21200M -0.23900M -0.81900M
Total revenue 17.20M 5.90M 7.50M 10.21M 7.46M
Total operating expenses 74.51M 48.98M 76.79M 90.78M 115.06M
Cost of revenue 5.13M 41.07M 54.92M 63.57M 85.73M
Total other income expense net -39.36900M -4.00000M 6.48M 6.27M 18.69M
Discontinued operations - - - - -
Net income from continuing ops -102.14200M -87.95600M -81.88900M -91.34700M -98.81100M
Net income applicable to common shares -102.14200M -87.95600M -81.88900M -91.34700M -98.81100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 784.68M 669.15M 669.41M 662.14M 744.72M
Intangible assets 437.37M 441.28M 442.73M 444.20M 446.09M
Earning assets - - - - -
Other current assets - - 0.40M 5.40M 6.76M
Total liab 187.24M 188.80M 167.58M 165.10M 163.32M
Total stockholder equity 597.44M 480.36M 501.84M 497.04M 581.40M
Deferred long term liab - - - - -
Other current liab 16.73M 4.65M 5.43M 2.19M 74.67M
Common stock - 1310.81M 1249.12M 1165.31M 1163.15M
Capital stock 1508.85M 1310.81M 1249.12M 1165.31M 1163.15M
Retained earnings -1010.90300M -908.76100M -820.80500M -738.91600M -647.56900M
Other liab - - 19.11M 15.02M 19.52M
Good will 134.45M 134.45M 134.45M 134.45M 134.45M
Other assets - - 2.33M 1.93M 1.72M
Cash 161.16M 62.56M 70.92M 60.03M 136.88M
Cash and equivalents - - -0.00200M 0.01M -0.04900M
Total current liabilities 102.63M 73.24M 41.98M 51.37M 94.27M
Current deferred revenue - 45.04M 6.40M 17.91M -55.96500M
Net debt - 56.36M 45.58M 46.87M -31.38600M
Short term debt - 16.49M 10.01M 8.20M 55.97M
Short long term debt 54.16M 13.86M 5.95M 5.02M 53.20M
Short long term debt total - 118.92M 116.50M 106.91M 105.50M
Other stockholder equity - - -428.31800M -426.39300M -515.58400M
Property plant equipment - - 6.49M 9.96M 12.14M
Total current assets 204.35M 86.46M 81.66M 69.84M 148.23M
Long term investments 1.39M 1.01M 1.76M 1.76M 2.08M
Net tangible assets - - -75.34500M -81.60800M 0.85M
Short term investments - - - - -
Net receivables 13.91M 20.95M 7.00M 4.40M 4.84M
Long term debt 67.74M 100.48M 102.81M 91.62M 41.05M
Inventory 22.25M - - - -0.25200M
Accounts payable 19.08M 7.07M 20.14M 23.08M 19.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 78.30M 73.52M 70.65M 65.81M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.47M 0.48M 0.48M 1.68M 1.72M
Deferred long term asset charges - - - - -
Non current assets total 580.33M 582.69M 587.76M 592.30M 596.49M
Capital lease obligations 6.26M 4.58M 7.73M 10.27M 11.25M
Long term debt total - - 106.48M 98.70M 49.53M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.12M -0.09700M -0.19400M -0.23200M -1.64700M
Change to liabilities - - -0.39800M 4.78M -5.06100M
Total cashflows from investing activities 0.12M -0.09700M -0.19400M -0.23200M -1.64700M
Net borrowings -9.76500M -13.52200M -2.65600M -6.32700M -2.93100M
Total cash from financing activities 147.34M 40.25M 74.50M -9.87000M 114.47M
Change to operating activities - - 0.43M -0.04800M -1.61800M
Net income -102.14200M -87.95600M -81.88900M -91.34700M -98.81100M
Change in cash 98.59M -8.35800M 10.87M -76.43400M 7.55M
Begin period cash flow 62.96M 71.32M 60.45M 136.88M 129.33M
End period cash flow 161.55M 62.96M 71.32M 60.45M 136.88M
Total cash from operating activities -49.95400M -48.45800M -63.26900M -65.78200M -106.68100M
Issuance of capital stock 161.21M 65.41M 88.64M 0.21M 106.27M
Depreciation 6.40M 4.67M 4.11M 4.38M 4.26M
Other cashflows from investing activities 0.56M -0.06000M 0.07M -0.07500M 0.12M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory 0.83M 0.00000M - - -
Change to account receivables 6.29M -15.46600M -0.11800M 0.14M -1.73900M
Sale purchase of stock 168.03M 65.41M 88.64M 8.29M 119.24M
Other cashflows from financing activities -4.10400M -11.63200M -11.47700M 48.17M 11.13M
Change to netincome - - 16.98M 16.32M -3.71600M
Capital expenditures 0.73M 0.33M 0.31M 0.23M 1.65M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.04200M -2.63100M -2.47200M 4.87M -8.41800M
Stock based compensation 22.09M 5.87M 3.65M 5.54M 12.51M
Other non cash items 26.41M 31.78M 13.54M 11.02M -15.40700M
Free cash flow -50.68400M -48.78900M -63.58300M -66.01400M -108.32800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MSB
Mesoblast Ltd		 0.10 4.61% 2.27 - 454.55 40.73 3.14 30.21 -9.8623
CSL
CSL Ltd		 2.93 2.62% 114.97 12.39 11.79 3.36 1.94 2.99 8.99
TLX
TELIX Pharmaceuticals Ltd		 0.88 6.04% 15.44 - 2000.00 6.04 8.25 4.67 106.76
NEU
Neuren Pharmaceuticals Ltd		 0.38 3.07% 12.76 57.61 52.08 25.89 4.85 20.81 61.06
PYC
PYC Therapeutics Ltd		 -0.015 0.96% 1.54 - 12.00 69.13 8.92 25.02 -8.4071

Reports Covered

Stock Research & News

View All

Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Ltd

55 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director 1957
Dr. Eric A. Rose M.D. Chief Medical Officer & Exec. Director 1951
Mr. Andrew Chaponnel B.Com. Interim Chief Fin. Officer NA
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. Chief Operating Officer 1964
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) Gen. Counsel & Corp. Exec. 1968
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders NA
Mr. Michael Schuster M.B.A., MS, BSc, MBA Head of Pharma Partnering 1977
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA Head of Regulatory Affairs & Quality Management NA
Mr. Justin Horst B.S. Head of Manufacturing NA
Ms. Niva Sivakumar B.Com., L.L.B. Joint Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.